Sanguine Biosciences is a pioneer of in-home specimen collection and a leader in direct-to-patient recruitment and digital health innovation. We partner with researchers on their study designs and support cross-sectional and longitudinal analyses with complex patient inclusion/exclusion sample collection criteria. Our growing community is made up of >30,000 medical record-verified, highly engaged, patient members, and >100 advocacy groups, allowing us to seamlessly work with the pharmaceutical industry to expedite and complete >600 pre-clinical and clinical condition-specific research studies to date. We’ve been cited in >80 scientific publications, including high-impact journals like Science, Blood, Science Advances, and Acta Neuropathologica, among others. Sanguine Biosciences is the proud recipient of a prestigious grant from the National Science Foundation that will further the development of a cutting-edge, direct-to-patient, electronic patient data aggregation platform aimed at streamlining clinical trial design and recruitment. We have also been featured in leading U.S news sources, including CBS News, Fox News, The Boston Globe, The Washington Post, The San Diego Tribune, San Fernando Valley Business Journal, and The San Francisco Chronicle.